Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives
Open accessAbstract
Type 2 diabetes mellitus (T2DM) is a progressive disease associated with significant morbidity and mortality. There is good evidence that intensive glycemic control reduces the development and progression of complications in patients with diabetes. In order to achieve glycemic targets, patients often require a combination of oral therapy and/or insulin in addition to lifestyle modification. Unfortunately many currently available therapies for T2DM are associated with weight gain and hypoglycemia resulting in poor compliance and subsequent worsening glycemic control. Glucagon like peptide-1 (GLP-1) is an incretin hormone secreted from the small intestine that lowers fasting and postprandial glucose through multiple mechanisms including glucose-dependent insulin secretion, reduction of glucagon secretion, delaying gastric emptying and increased satiety. Liraglutide is a long acting GLP-1 mimetic that is administered once a day by subcutaneous injection and is now licensed for the treatment of T2DM. Phase 3 clinical trials have demonstrated beneficial effects on glycemic control and weight with liraglutide therapy. Within this article, we provide an overview of pharmacology, efficacy, safety and patient experience on liraglutide in the management of T2DM.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Liraglutide and exenatide have 97% and 52% homology with GLP-1, respectively.
“Liraglutide and exenatide (synthetic exendin-4) have 97 and 52%, respectively, homology with GLP-1.255,256”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [255]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419 · see citing works
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807 · see citing works
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · see citing works
Creager, M. A., Lüscher, T. F., of, P. W. T. A., Cosentino, F., & Beckman, J. A. (2003) · Circulation · doi:10.1161/01.cir.0000091257.27563.32 · Cited by 1,654 · see citing works
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · see citing works
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I
Paneni, F., Beckman, J. A., Creager, M. A., & Cosentino, F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht149 · Cited by 1,421 · see citing works
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · see citing works
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · see citing works
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · see citing works
Molecular Understanding of Hyperglycemia's Adverse Effects for Diabetic Complications
Sheetz, M. J. (2002) · JAMA · doi:10.1001/jama.288.20.2579 · Cited by 1,003 · see citing works
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · see citing works
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835 · see citing works
Marre, M., Shaw, J. E., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M. D., Thi, T. D. L., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 814 · see citing works
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795 · see citing works
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 705 · see citing works
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · see citing works
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 576 · see citing works
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · see citing works
Hypoglycaemia in Type 2 diabetes
Amiel, S. A., Dixon, T., Mann, R., & Jameson, K. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02341.x · Cited by 472 · see citing works
Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes
Noel, R. A., Braun, D. K., Patterson, R. E., & Bloomgren, G. (2009) · Diabetes Care · doi:10.2337/dc08-1755 · Cited by 434 · see citing works
Madsbad, S., Schmitz, O., Ranstam, J., Jakobsen, G., Matthews, D. R., & on behalf of the NN2211-1310 International Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1335 · Cited by 312 · see citing works
Näslund, E. B., Gutniak, M., Skogar, S., Rössner, S., & Hellström, P. M. (1998) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.3.525 · Cited by 307 · see citing works
Juhl, C. B., Hollingdal, M., Sturis, J., Jakobsen, G., Agersø, H., Veldhuis, J. D., Pørksen, N. K., & Schmitz, O. (2002) · Diabetes · doi:10.2337/diabetes.51.2.424 · Cited by 264 · see citing works
Liu, H., Dear, A. E., Knudsen, L. B., & Simpson, R. W. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0468 · Cited by 187 · see citing works
The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro
Bregenholt, S., Møldrup, A., Blume, N., Karlsen, A. E., Friedrichsen, B. N., Tornhave, D., Knudsen, L. B., & Petersen, J. S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.013 · Cited by 170 · see citing works
Feinglos, M. N., Saad, M. F., Pi-Sunyer, F. X., An, B., Santiago, O. M., & on behalf of the Liraglutide Dose‐Response Study Group (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01567.x · Cited by 151 · see citing works
Hypoglycemia as a barrier to glycemic control
Davis, S. N., & Alonso, M. D. (2004) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(03)00058-8 · Cited by 143 · see citing works
Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors
Hauner, H., Stockamp, B., & Haastert, B. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1211431 · Cited by 140 · see citing works
Seino, Y., Rasmussen, M. F., Zdravkovic, M., & Kaku, K. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.03.018 · Cited by 119 · see citing works
de Heer, J., & Holst, J. J. (2007) · Diabetes · doi:10.2337/db06-0738 · Cited by 115 · see citing works
Overstimulation and beta-cell function.
Grill, V., & Björklund, A. (2001) · Diabetes · doi:10.2337/diabetes.50.2007.s122 · Cited by 97 · see citing works
Mari, A., Degn, K., Brock, B., Rungby, J., Ferrannini, E., & Schmitz, O. (2007) · Diabetes Care · doi:10.2337/dc07-0310 · Cited by 84 · see citing works
Incretin Mimetics as Emerging Treatments for Type 2 Diabetes
Joy, S. V., Rodgers, P. T., & Scates, A. C. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e245 · Cited by 71 · see citing works
Keating, G. M. (2005) · Drugs · doi:10.2165/00003495-200565120-00008 · Cited by 64 · see citing works
Hypoglycaemia in Type 2 diabetes
Heller, S. R. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.09.026 · Cited by 55 · see citing works
Leahy, J. L., & Kennedy, L. (2006) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70593-5 · Cited by 46 · see citing works
Raskin, P., Gerich, J., Blonde, L., et al. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/cn5s-c680 · Cited by 36 · see citing works
Leahy, J. L., & Kennedy, L. (2006) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70285-3 · Cited by 34 · see citing works
Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide
González, C. D., Beruto, V., Keller, G. A., Santoro, S., & Girolamo, G. D. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.8.887 · Cited by 30 · see citing works
Exenatide and pancreatitis: an update
Bain, S. C., & Stephens, J. W. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740330802432003 · Cited by 27 · see citing works
Self-citationThe physiology and pharmacology of incretins in type 2 diabetes mellitus
Holst, J. J. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00920.x · Cited by 27 · see citing works
Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm
Green, J., & Feinglos, M. N. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01438.x · Cited by 17 · see citing works
Abdominal Lipohypertrophy Caused by Injections of Growth Hormone: A Case Report
Ruvalcaba, R. H. A., & Kletter, G. B. (1998) · PEDIATRICS · doi:10.1542/peds.102.2.408 · Cited by 11 · see citing works
Safety and adverse effects associated with GLP-1 analogues
Stephens, J. W., & Bain, S. C. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.4.417 · Cited by 10 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- [4]The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group N Engl J Med 1993 329 14 977 986 8366922
- [27]Nauck M Frid A Hermansen K Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study Diabetes Care 2009 32 1 84 90 18931095 PMC2606836
Cited by
Sorted by citations
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441 · see citing works
Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies
Gerich, J. E. (2013) · International Journal of General Medicine · doi:10.2147/ijgm.s51665 · Cited by 84 · see citing works
Davies, M. J., & Speight, J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01595.x · Cited by 54 · see citing works
Henry, R. R., Rosenstock, J., Logan, D. K., Alessi, T. R., Luskey, K. L., & Baron, M. A. (2013) · Diabetes Care · doi:10.2337/dc12-2410 · Cited by 43 · see citing works
Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling
Thompson, K. A. (2013) · Clinical and Experimental Pharmacology · doi:10.4172/2161-1459.1000138 · Cited by 34 · see citing works
Wang, Y., Li, L., Yang, M., Liu, H., Boden, G., & Yang, G. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01436.x · Cited by 30 · see citing works
Baruah, M., Kalra, S., Unnikrishnan, A., Raza, S., Somasundaram, N. P., John, M., Katulanda, P., Shrestha, D., Bantwal, G., Sahay, R. K., et al. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.81935 · Cited by 28 · see citing works
Liu, F., Dong, J., Yang, Q., Xue, X., Ren, Z., Gan, Y., & Liao, L. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12200 · Cited by 20 · see citing works
Germano, J. D. F., Huang, C., Sin, J., Song, Y., Tucker, K. C., Taylor, D. J. R., Saadaeijahromi, H., Stotland, A. B., Piplani, H., Gottlieb, R. A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-64924-2 · Cited by 20 · see citing works
Thompson, A., Stephens, J. W., Bain, S. C., & Kanamarlapudi, V. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154229 · Cited by 19 · see citing works
Self-citationGupta, S. N., Singhal, N. K., Ganesh, S., & Sandhir, R. (2018) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527317666181114163515 · Cited by 16 · see citing works
Htike, Z. Z., Khunti, K. K., & Davies, M. J. (2012) · Diabetes Therapy · doi:10.1007/s13300-012-0003-x · Cited by 13 · see citing works
The Influence of Incretin Mimetics on Cardiovascular Risk Factors in Diabetes
Kinalska, I., Bednarska-Chabowska, D., Adamiec-Mroczek, J., & Hak, Ł. (2012) · ISRN Endocrinology · doi:10.5402/2012/625809 · Cited by 4 · see citing works
Exploring the structure, function & regulation of the human glucagon-like peptide-1 receptor
Huang, Y. (2011) · Figshare · Cited by 1 · see citing works
Module 18. Update on pharmacological options in the management of type 2 diabetes
Meetoo, D. D. (2012) · Nurse Prescribing · doi:10.12968/npre.2012.10.12.cpd3
Module 8. The Management of Type 2 Diabetes: Pharmacological Options
Meetoo, D. D. (2010) · Nurse Prescribing · doi:10.12968/npre.2010.8.12.cpd1
Clinical Potential of Glucagon-like Peptide-1 Analogs in the Management of Diabesity
Sharma, N., & Singh, S. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_102_22
- Authors
- Stephens, J., & Edavalath, M.
- Affiliations
- Morriston Hospital (GB)
- Corresponding author
- Stephens, Jeffrey
- ORCID
- Stephens, Jeffrey
- Venue
- Patient Preference and Adherence
- Publisher
- Informa UK Limited
- Published
- 2010-03
- Volume
- 4
- Pages
- 61
- ISSN
- 1177-889X (ISSN-L)
- PMC
- PMC2846140
- OpenAlex
- W2054119569
- Cited by
- 17
- References
- 45
- Citations by year
- 2023: 1 · 2021: 1 · 2020: 1 · 2018: 1 · 2016: 1 · 2014: 1 · 2013: 3 · 2012: 4
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Patient Preference and Adherence (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, type 2 diabetes, GLP-1 receptor agonists, incretin-based therapy, glycemic control, weight loss, patient adherence, patient experience, drug safety, hypoglycemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
